All articles by Abigail Beaney

Abigail Beaney

Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail

Lilly’s triple G agonist succeeds in Phase III diabetes trial

Eli Lilly’s investigational first-in-class GIP, glucagon-like peptide 1 receptor (GLP-1R) and glucagon triple hormone receptor agonist has met its primary endpoints in…
Aspen’s personalised Parkinson’s cell therapy to advance to Phase III

Aspen Neuroscience’s autologous, personalised stem cell therapy is set for a pivotal trial after it showed improved "ON" and "OFF"…
Pfizer’s oral CDK4 inhibitor shows promise in second-line breast cancer

Pfizer’s oral cyclin-dependent kinase 4 (CDK4) inhibitor, atirmociclib, has met the primary endpoint in a Phase II trial as a…
Rhythm’s Imcivree fails Phase III rare disease obesity trial

A Phase III trial of Rhythm Pharmaceuticals’ Imcivree (setmelanotide) failed to meet its primary endpoints in four rare, genetically driven…
BioMarin discontinues dosing in certain Voxzogo trials after safety concern

BioMarin has discontinued dosing and enrolment in Phase II trials of Voxzogo (vosoritide) in Turner Syndrome, SHOX-deficiency and Aggrecan (ACAN)-deficiency…

Lilly’s Ebglyss shows AD benefit in children as young as six months

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) has reduced the severity of atopic dermatitis (AD) in children as young as six months, with…
Ultragenyx’s gene therapy meets co-primary endpoint in Phase III trial

Ultragenyx Pharmaceutical’s gene therapy for ornithine transcarbamylase (OTC) deficiency has shown benefit in a Phase III trial, hitting one of…
Biogen’s Spinraza successor benefits SMA patients unresponsive to gene therapy

Biogen’s successor to Spinraza (nusinersen) has shown benefit in spinal muscular atrophy (SMA) patients who had suboptimal clinical status despite…
Vertex to seek approval of IgAN drug after Phase III success

Vertex Pharmaceuticals will head to US regulators after its immunoglobulin A nephropathy (IgAN) drug povetacicept was successful in a Phase…
Roche’s oral SERD fails in Phase III breast cancer trial

Roche’s oral selective oestrogen receptor degrader (SERD) has failed to meet its primary endpoint in a Phase III breast cancer…